Arrhythmia Research Technology (HRT) Posts Surprise Q3 Loss

Arrhythmia Research Technology (NYSE: HRT) reported Q3 EPS of ($0.10), $0.60 worse than the analyst estimate of $0.50. Revenue for the quarter came in at $5.23 million versus the consensus estimate of $136.4 million.

For earnings history and earnings-related data on Arrhythmia Research Technology (HRT) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• South Plains Financial Inc. (SPFI) Tops Q2 EPS by 1c
• Cantor Fitzgerald Reiterates Overweight Rating on DBV Technologies S.A (DBVT)